CALC vs. NXTC, NBRV, APLM, XLO, DARE, JAGX, AADI, BOLT, RMTI, and OCUP
Should you be buying CalciMedica stock or one of its competitors? The main competitors of CalciMedica include NextCure (NXTC), Nabriva Therapeutics (NBRV), Apollomics (APLM), Xilio Therapeutics (XLO), Daré Bioscience (DARE), Jaguar Health (JAGX), Aadi Bioscience (AADI), Bolt Biotherapeutics (BOLT), Rockwell Medical (RMTI), and Ocuphire Pharma (OCUP). These companies are all part of the "pharmaceutical preparations" industry.
NextCure (NASDAQ:NXTC) and CalciMedica (NASDAQ:CALC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, community ranking, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.
42.7% of NextCure shares are owned by institutional investors. 11.9% of NextCure shares are owned by company insiders. Comparatively, 53.3% of CalciMedica shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
CalciMedica's return on equity of -47.03% beat NextCure's return on equity.
NextCure received 67 more outperform votes than CalciMedica when rated by MarketBeat users. However, 100.00% of users gave CalciMedica an outperform vote while only 63.03% of users gave NextCure an outperform vote.
NextCure is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks.
In the previous week, NextCure and NextCure both had 2 articles in the media. CalciMedica's average media sentiment score of 0.00 equaled NextCure'saverage media sentiment score.
NextCure currently has a consensus target price of $6.00, indicating a potential upside of 334.78%. CalciMedica has a consensus target price of $18.67, indicating a potential upside of 238.16%. Given CalciMedica's higher probable upside, analysts plainly believe NextCure is more favorable than CalciMedica.
NextCure has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500. Comparatively, CalciMedica has a beta of 1.61, meaning that its stock price is 61% more volatile than the S&P 500.
Summary
NextCure and CalciMedica tied by winning 6 of the 12 factors compared between the two stocks.
Get CalciMedica News Delivered to You Automatically
Sign up to receive the latest news and ratings for CALC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CALC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CalciMedica Competitors List
Related Companies and Tools
